184 related articles for article (PubMed ID: 7813387)
1. Comparison of cardiotoxicity of pirarubicin, epirubicin and doxorubicin in the rat.
Hirano S; Wakazono K; Agata N; Iguchi H; Tone H
Drugs Exp Clin Res; 1994; 20(4):153-60. PubMed ID: 7813387
[TBL] [Abstract][Full Text] [Related]
2. Effects of pirarubicin in comparison with epirubicin and doxorubicin on the contractile function in rat isolated cardiac muscles.
Hirano S; Agata N; Iguchi H; Tone H
Gen Pharmacol; 1995 Oct; 26(6):1339-47. PubMed ID: 7590129
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin cardiotoxicity in the rat: comparison of electrocardiogram, transmembrane potential, and structural effects.
Jensen RA; Acton EM; Peters JH
J Cardiovasc Pharmacol; 1984; 6(1):186-200. PubMed ID: 6199603
[TBL] [Abstract][Full Text] [Related]
4. Electrocardiographic and transmembrane potential effects of 5-iminodaunorubicin in the rat.
Jensen RA; Acton EM; Peters JH
Cancer Res; 1984 Sep; 44(9):4030-9. PubMed ID: 6744318
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin cardiotoxicity: contractile changes after long-term treatment in the rat.
Jensen RA
J Pharmacol Exp Ther; 1986 Jan; 236(1):197-203. PubMed ID: 3941392
[TBL] [Abstract][Full Text] [Related]
6. [The prevention of the myocardial toxicity of doxorubicin with superoxide dismutase].
Villani F; Galimberti M; Favalli L; Rozza A; Lanza E; Poggi P
G Ital Cardiol; 1991 Jun; 21(6):633-41. PubMed ID: 1743445
[TBL] [Abstract][Full Text] [Related]
7. Dissociation between in vitro cytotoxicity and in vivo cardiotoxicity of two new anthracyclines: 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin and 4'-deoxy-4'-iodo-doxorubicin.
Pinna A; Agen C; Di Paolo A; Innocenti F; Nardini D; Danesi R; Del Tacca M
J Environ Pathol Toxicol Oncol; 1994; 13(1):25-31. PubMed ID: 7823290
[TBL] [Abstract][Full Text] [Related]
8. Protective effects of caffeic acid phenethyl ester on doxorubicin-induced cardiotoxicity in rats.
Fadillioglu E; Oztas E; Erdogan H; Yagmurca M; Sogut S; Ucar M; Irmak MK
J Appl Toxicol; 2004; 24(1):47-52. PubMed ID: 14745846
[TBL] [Abstract][Full Text] [Related]
9. Trifluoperazine does not affect doxorubicin cardiotoxicity in the rat.
Villani F; Monti E; Piccinini F; Favalli L; Rozza Dionigi A; Lanza E; Poggi P
Anticancer Res; 1988; 8(4):659-63. PubMed ID: 3178155
[TBL] [Abstract][Full Text] [Related]
10. Continuous electrocardiogram reveals differences in the short-term cardiotoxic response of Wistar-Kyoto and spontaneously hypertensive rats to doxorubicin.
Hazari MS; Haykal-Coates N; Winsett DW; Costa DL; Farraj AK
Toxicol Sci; 2009 Jul; 110(1):224-34. PubMed ID: 19407338
[TBL] [Abstract][Full Text] [Related]
11. [The effect of superoxide dismutase and catalase on the delayed toxicity of doxorubicin].
Villani F; Galimberti M; Poggi P; Rozza A; Lanza E; Favalli L; Scavini C
Cardiologia; 1992 Oct; 37(10):709-11. PubMed ID: 1296877
[TBL] [Abstract][Full Text] [Related]
12. General and cardiac toxicity of doxorubicin-loaded gelatin nanoparticles.
Leo E; Arletti R; Forni F; Cameroni R
Farmaco; 1997; 52(6-7):385-8. PubMed ID: 9372590
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of cardiotoxicity of a new anthracycline derivative: 4'-deoxy-4'-iodo-doxorubicin.
Villani F; Galimberti M; Lanza E; Rozza A; Favalli L; Poggi P
Invest New Drugs; 1988 Sep; 6(3):173-8. PubMed ID: 3192383
[TBL] [Abstract][Full Text] [Related]
14. Acute doxorubicin cardiotoxicity is successfully treated with the phytochemical oleuropein through suppression of oxidative and nitrosative stress.
Andreadou I; Sigala F; Iliodromitis EK; Papaefthimiou M; Sigalas C; Aligiannis N; Savvari P; Gorgoulis V; Papalabros E; Kremastinos DT
J Mol Cell Cardiol; 2007 Mar; 42(3):549-58. PubMed ID: 17223128
[TBL] [Abstract][Full Text] [Related]
15. Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats.
Giri SN; Al-Bayati MA; Du X; Schelegle E; Mohr FC; Margolin SB
Cancer Chemother Pharmacol; 2004 Feb; 53(2):141-50. PubMed ID: 14564477
[TBL] [Abstract][Full Text] [Related]
16. [A comparative study of 4'-epi-doxorubicin and doxorubicin cardiotoxicities].
Suzuki T; Yamamoto H; Iwasaki T; Okamoto S; Iizuka T; Kanda H; Murata K
Gan To Kagaku Ryoho; 1984 Oct; 11(10):2170-6. PubMed ID: 6593004
[TBL] [Abstract][Full Text] [Related]
17. Morphine is protective against doxorubicin-induced cardiotoxicity in rat.
Kelishomi RB; Ejtemaeemehr S; Tavangar SM; Rahimian R; Mobarakeh JI; Dehpour AR
Toxicology; 2008 Jan; 243(1-2):96-104. PubMed ID: 17988779
[TBL] [Abstract][Full Text] [Related]
18. [Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer].
Tominaga T; Kitamura M; Hayashi K; Takahashi I; Kosaki G
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1669-74. PubMed ID: 6591857
[TBL] [Abstract][Full Text] [Related]
19. Anthracycline cardiotoxicity in the rat: relationship between ECG changes and morphologic effects induced by different analogues.
Villani F; Favalli L; Lanza E; Rozza-Dionigi A; Poggi P
Chemioterapia; 1987 Jun; 6(2 Suppl):688-90. PubMed ID: 3509523
[No Abstract] [Full Text] [Related]
20. Metabonomic study on the cumulative cardiotoxicity of a pirarubicin liposome powder.
Cong W; Liang Q; Li L; Shi J; Liu Q; Feng Y; Wang Y; Luo G
Talanta; 2012 Jan; 89():91-8. PubMed ID: 22284464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
